Corrigendum: Polybromo 1/Vimentin Axis in Pancreatic Cancer

Reconciled focus on a corrected figure label in a PDAC study

Suppression of vimentin in Pbrm1-null PDAC cells mitigated dedifferentiation, EMT, and metastasis in this context.

• The work investigates how loss of Polybromo 1 (PBRM1), a component of the SWI/SNF chromatin remodeling complex, influences pancreatic ductal adenocarcinoma (PDAC) progression, tumor grade, epithelial-mesenchymal transition (EMT), and metastasis.
• In mouse models combining Kras mutations and Trp53 deletions, pancreas-specific Pbrm1 loss accelerated poorly differentiated PDAC development and promoted EMT features, including elevated vimentin expression.
• The research links PBRM1 function to regulation of vimentin, and reports that PBRM1 directly binds the vimentin promoter to suppress its expression.
• Human PDAC data described in the study show that reduced PBRM1 expression correlates with higher vimentin levels, poorly differentiated histology, higher recurrence, and shorter overall survival; PDAC with PBRM1 deletion aligns with an aggressive squamous molecular subtype.
• Overall interpretation presented by the authors positions PBRM1 as a tumor suppressor whose loss promotes tumor grade progression and metastasis by upregulating vimentin.

• A corrigendum was issued to address a labeling error in Figure 4H of the original article, wherein the labels “KP –/– C” and “KP –/– CPb –/–” were inadvertently swapped.
• The figure panel has been corrected, and the HTML and PDF versions of the paper have been updated accordingly.

• The corrected article centers on preclinical model findings (genetic manipulation in mice) and associated molecular analyses (gene expression and promoter binding).
• It also references correlative observations in human PDAC cohorts linking PBRM1 status with EMT markers and clinical outcomes.
• Specific numerical results, exact statistical values, and detailed outcomes are not provided in the corrigendum text; the correction focuses on updating the figure labeling to ensure accurate interpretation of the presented data.

• The corrigendum explicitly states the labeling error and its correction, without introducing new experimental data or conclusions beyond the amendment.
• There is no new evidence presented in the corrigendum beyond the figure correction; the broader conclusions about PBRM1’s role remain as described in the original report.

• Researchers referencing the figure should rely on the corrected panel arrangement to interpret the experimental conditions associated with the KP genotypes and their impact on PDAC-related phenotypes.